Skip to content

Bausch + Lomb BLCO Additional Paid-In Capital

Additional Paid-In Capital at other companies

The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$1.98B+2.1%
Glaukos logo
GlaukosGKOS
$1.62B+6.3%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$782.84M+7.6%
Warby Parker logo
Warby ParkerWRBY
$1.06B+1.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$14.4B+9.2%
Solventum logo
SolventumSOLV
$3.9B+3.0%

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.43B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's additional paid-in capital?
Bausch + Lomb (BLCO) reported additional paid-in capital of $8.58B in Q1 2026.
How has Bausch + Lomb's additional paid-in capital changed year-over-year?
Bausch + Lomb's additional paid-in capital increased by 1.6% year-over-year, from $8.45B to $8.58B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.